Thirumoorthy et al. 2007 — Metallothionein: an overview

Thirumoorthy and colleagues at the KMCH College of Pharmacy (Coimbatore, Tamil Nadu) and the Department of Pharmaceutical Technology, Jadavpur University (Kolkata) review the published literature on metallothionein (MT) — a low-molecular-weight (Mr ≈ 6000), sulfhydryl-rich, divalent-metal-binding protein discovered by Margoshes and Vallee in 1957. The four-page narrative is organised as a short orientation to MT classification, structure, protective biology, role in carcinogenesis and apoptosis, anti-cancer-drug response, and an immunohistochemical staining protocol used by the authors’ group to detect MT-1 in cold-acetone-fixed paraffin-embedded liver sections. The paper reports no primary chemical or toxicological measurements; its value to the wiki is conceptual — it organises the MT-I/MT-II/MT-III/MT-IV isoform vocabulary and the cysteine-thiolate metal-binding chemistry that the downstream cadmium- and mercury-handling literature draws on.

Why this matters

• The review identifies the canonical MT substrates as divalent heavy metals: “MTs bind a number of trace metals including cadmium, mercury, platinum and silver, and also protect cells and tissues against heavy metal toxicity” (source p. 993, Characteristics of MTs). MT is concurrently described as the most abundant intracellular reservoir for the essential ions zinc and copper.
• It catalogues the human MT family as four classes (MT-1, MT-2, MT-3, MT-4) encoded by 10 functional isoforms, with MT-1 comprising the subtypes MT-1A, MT-1B, MT-1E, MT-1F, MT-1G, MT-1H, and MT-1X, and MT-2 encoded by a single MT-2A gene (source p. 993, Classification of MTs). MT-1 and MT-2 are described as ubiquitously expressed and stress-inducible.
• It positions MT as a homeostatic detoxifier of heavy metals and a scavenger of reactive oxygen metabolites — particularly the hydroxyl radical — with the protective effect framed as central to MT’s dual role in normal cell maintenance and in cancer-cell drug resistance (source p. 994, Role of MT in detoxification).
• It surveys MT as a potential prognostic biomarker in invasive ductal carcinoma of the breast, skin (malignant melanoma), cervix, and pancreas (source p. 994, Role of MT in detoxification, citing refs 9–12), and reports that vanadium at 0.5 ppm suppresses MT and Ki-67 expression in preneoplastic rat liver in a 2-acetylaminofluorene (2-AAF) hepato-carcinogenesis model (source p. 995, Markers of carcinogenesis, citing Chakraborty et al. ref 15).

Key concepts and structure

The review is organised as an abstract, a brief introduction, three topical sections (Classification of MTs; Characteristics of MTs; MT as Tumor Marker with subsections on alteration in MT function due to carcinogenesis, protective functions, relation to apoptosis), a fourth section on MT in pathophysiological processes (detoxification, dual functions, response to anti-cancer drugs, over-expression, genotoxic/non-genotoxic effects, stem cell mutation, low MT susceptibility, markers of carcinogenesis, MT as antioxidant, factors influencing synthesis), and a fifth section describing the immunostaining method used by the authors’ group. It cites 17 references spanning 1988 to 2005.

Classification (source Classification of MTs, p. 993)

MTs are described as a family of Mr ≈ 6000 proteins comprised of four classes (MT-Ⅰ, MT-Ⅱ, MT-Ⅲ, MT-Ⅳ) with multiple isoforms within each class. MT-Ⅰ and MT-Ⅱ are ubiquitously expressed and stress-inducible; MT-Ⅰ isoform inducibility is reported to depend on the embryonic germ layer from which a tumour is derived. In humans, MTs are encoded by a family of 10 functional isoform genes subdivided into MT-1, MT-2, MT-3, and MT-4 protein groups. A single MT-2A gene encodes MT-2 protein; MT-1 protein comprises multiple subtypes encoded by the MT-1A, MT-1B, MT-1E, MT-1F, MT-1G, MT-1H, and MT-1X genes, accounting for what the review terms the “micro-heterogeneity” of the MT-1 protein. Different MT genes in humans are described as potentially playing different functional roles during development and under various physiological conditions.

Characteristics (source Characteristics of MTs, p. 993)

MTs are characterised by unusually high cysteine content (≈ 30 %) and the absence of aromatic amino acids. Their rich thiol content underlies binding of trace metals — explicitly cadmium, mercury, platinum, and silver are named — and protection of cells and tissues against heavy metal toxicity. The review additionally describes MTs as the most abundant intracellular reservoir for zinc and copper, with metal–thiolate fractions described as “dynamic and of high affinity” and facilitating metal exchange in tissues. MTs are present in a great variety of eukaryotes and function as anti-oxidants and protectors against hydroxyl free radicals. The review invokes nasopharyngeal carcinoma as a context in which the MT antioxidant function is clinically relevant, since these tumours are markedly radio-sensitive and radiotherapy kills cells through free-radical-induced apoptosis.

MT as tumour marker (source pp. 993–994)

The review groups MT-related tumour biology into four sub-claims: (1) carcinogenesis is a dynamic, multi-hit process in which genetic damage accumulates over years to decades and most early lesions disappear spontaneously; (2) MT has high affinity for bivalent metal ions, is over-expressed in rapidly proliferating normal, regenerating, and cancer cells, and protects cells against the cytotoxic effects of electrophilic anticancer drugs through mechanisms beyond simple covalent binding; (3) enhanced MT expression confers anti-apoptotic effects, while MT-null cells show increased susceptibility to apoptotic death after anticancer-drug exposure, and 18-mer antisense down-regulation of MT in MCF-7 cells inhibits growth and initiates apoptosis (source p. 994, citing Abdel-Mageed and Agrawal, ref 8); (4) MT serves as a candidate prognostic marker in invasive ductal carcinoma of the breast, skin (malignant melanoma), cervix, and pancreas (refs 9–12).

MT in pathophysiological processes (source pp. 994–995)

The fourth section catalogues MT’s role in detoxification, dual functions in cell survival, response to anti-cancer drugs, and over-expression in chemo-resistance. Sub-claims with quantitative or mechanistic anchors:

• MT scavenges reactive oxygen metabolites, particularly the hydroxyl radical, that are produced continuously during normal aerobic metabolism and can become noxious when imbalanced with endogenous antioxidants, inducing DNA damage, lipid peroxidation, and enzyme oxidation (source p. 994, Role of MT in detoxification).
• MTs are induced by endogenous and exogenous stimuli including glucocorticoids, interferon, interleukin-1, progesterone, vitamin D₃, endotoxins, serum factors, and heavy metals (source p. 994, Dual functions of MT).
• MT over-expression in ovarian cancer is proposed to induce chemo-resistance by sequestering drugs or their metabolites and preventing their interaction with intracellular targets, although two independent investigator groups have been unable to find a direct causal relationship between MT expression and chemo-resistance (source p. 994, Over expression of MT).
• Stable crypt-restricted MT immunopositivity is described as a stem-cell mutation marker for mouse colon, validated against the glucose-6-phosphate dehydrogenase (G6PD) assay, with MT-immunopositive crypt frequency showing dose-response to three different chemical mutagens (source p. 995, Stem cell mutation, citing Donnelly et al. ref 13).
• Vanadium at a dose of 0.5 ppm suppresses MT and Ki-67 expression in 2-acetylaminofluorene (2-AAF)-induced preneoplastic rat liver, and modulates p53 expression and apoptosis in this defined rat model of experimental hepato-carcinogenesis (source p. 995, Markers of carcinogenesis, citing Chakraborty et al. ref 15).
• Colorectal and gastric carcinogenesis is associated with a significant increase in the level of manganese-containing superoxide dismutase (Mn-SOD), an antioxidant enzyme that detoxifies superoxide to hydrogen peroxide (source p. 995, MT as anti-oxidants).

Immunostaining protocol (source pp. 995–996)

The fifth section describes the immunohistochemical detection protocol used by the authors’ group on cold-acetone-fixed paraffin-embedded liver sections (attributed to Jin et al. 2002). Five-micrometre sections on poly-L-lysine-coated slides were deparaffinised and rehydrated; endogenous peroxidase activity was blocked with 1 % H₂O₂ in 0.1 mol/L Tris-NaCl (pH 7.6) for 30 min; sections were incubated with 5 % normal goat serum for 1 h at 37 ℃, then overnight at 4 ℃ with primary antibody (rabbit anti-rat MT-1) in 1 % BSA at 1:50 dilution; biotinylated secondary antibody (goat anti-rabbit IgG, Sigma) was applied for 30 min at 37 ℃ at 1:200 dilution; streptavidin peroxidase (1:100) was applied for 1 h; chromogen development used 0.5 % 3,3′-diaminobenzidine tetrahydrochloride (DAB) and 0.33 % H₂O₂ in 0.5 mol/L Tris-NaCl as substrate; sections were counterstained with Harris haematoxylin, dehydrated, and mounted. Negative control omitted the primary antibody. MT immunoreactivity was scored as the percentage of immuno-positive cells across 10 randomly chosen high-power fields.

Methods (brief)

The paper is a narrative review with no original experimental work and no primary chemical, biological, or toxicological measurements. The exception is the Immunostaining of MT section, which describes a streptavidin-avidin-biotin immunoperoxidase protocol used by the authors’ group (attributed to Jin et al. 2002) for MT-1 detection on cold-acetone-fixed paraffin-embedded liver sections — but no primary results from that protocol are reported in this paper. The reference list contains 17 entries spanning 1988 (Kägi and Schäffer, Biochemistry) to 2005 (Chakraborty et al., J Cell Biochem; Donnelly et al., Br J Cancer). The review does not declare a formal search strategy, inclusion/exclusion criteria, PRISMA flow, or risk-of-bias assessment.

The journal (World Journal of Gastroenterology, The WJG Press) published the article under closed copyright (”© 2007 The WJG Press. All rights reserved.”) with no Creative Commons licence on this 2007 issue. The article was received 27 July 2006, accepted 10 January 2007, and published 21 February 2007 in volume 13, issue 7, pages 993–996. The PDF does not state a DOI explicitly; the access URL printed in the article is http://www.wjgnet.com/1007-9327/13/993.asp. No funding source or conflict-of-interest declaration appears in the PDF.

Key numbers

The review reports no contamination measurements, no exposure values, and no MT quantification of its own. The numeric anchors present in the text are mechanism/dose values cited to underlying primary references, and a small set of methodological constants from the immunostaining protocol:

Implications

• Certification: The review contributes no occurrence data and no exposure data, so it does not move any HMTc threshold-setting work. It is mechanistic background for any future mitigation chapter and for the cadmium- and mercury-toxicology sections of the relevant metal pages.
• App: No routing to ingredient or product pages. This source contributes background reading for cadmium (MT as the canonical Cd-binding intracellular protein) and mercury (MT named alongside cadmium as a divalent-metal substrate), and feeds no contamination-occurrence or exposure-assessment downstream.
• Courses: Useful as a four-page single-source orientation to MT biology — discovery history, isoform vocabulary, cysteine-thiolate metal binding, and the dual antioxidant/anti-apoptotic functions — for an educator-audience module on heavy-metal cellular handling. The 2007 vintage means specific tumour-biomarker and chemo-resistance claims should be cross-checked against the more recent reviews on the same topic (ruttkay-nedecky2013-metallothionein-oxidative-stress, yang2024-metallothionein-comprehensive-review) before propagation.
• Microbiome: Marginal. The review does not engage the gut microbiome or the heavy-metal-microbiome axis. WikiBiome federation is unlikely to draw on this source.

Limitations

This is a short (four-page) narrative review with no declared search strategy, no inclusion or exclusion criteria, no PRISMA flow, and no risk-of-bias assessment. Quantitative claims are mostly framed at the level of mechanism (the 30 % cysteine content; the 10-isoform human genetic family; the 0.5 ppm vanadium chemo-prevention dose) rather than as primary measurements with confidence intervals or sample sizes. The reference list of 17 entries is small relative to the breadth of the topic, and most underlying primary papers are cited once with a single sentence summary; quantitative claims should be traced to the underlying primary references before propagation to downstream synthesis pages. Coverage of heavy metals other than cadmium and mercury is limited: platinum and silver are named as MT substrates but not developed; arsenic, lead, nickel, chromium, aluminium, and tin do not appear. Speciation discipline (iAs vs tAs; MeHg vs tHg; Cr-III vs Cr-VI) is not addressed at all — mercury is named only as “mercury,” without speciation, so the wiki-page metals frontmatter records tHg rather than MeHg. The 2007 publication date predates a substantial body of MT mechanism work (notably the MT-redox-cycle and zinc-sulphur signalling literature consolidated in ruttkay-nedecky2013-metallothionein-oxidative-stress and the taxonomy and applications synthesis in yang2024-metallothionein-comprehensive-review); use as a historical and orientation source rather than a current authority. The review’s claims about MT as a tumour biomarker and its role in chemotherapy resistance are presented as the authors’ interpretation of heterogeneous primary studies rather than a meta-analytic synthesis.

Wiki pages this source may touch

• cadmium
• mercury
• remediation-evidence

Verification notes

Existing-page check. DOI grep is not applicable (the PDF does not print a DOI; the article URL is http://www.wjgnet.com/1007-9327/13/993.asp). Raw_handle grep (MFK_20-metallothionein-an-overview) and cite-key glob (thirumoorthy2007-*) over wiki/sources/ on 2026-06-08 returned no hits. Two existing sibling metallothionein-review pages were inspected for content overlap or duplication: ruttkay-nedecky2013-metallothionein-oxidative-stress (DOI 10.3390/ijms14036044) and yang2024-metallothionein-comprehensive-review (DOI 10.3390/antiox13070825). Both are distinct papers with distinct DOIs and distinct authors; the Thirumoorthy 2007 paper is the earliest of the three and is cited by the later reviews as foundational orientation. This is a NEW source page — no prior version to merge-enhance.

Evidence tier. B (secondary narrative review). The paper reports no primary measurements and declares no systematic search strategy. A-tier is reserved for primary peer-reviewed studies and authoritative agency monographs; this is neither. The review is published in a Scopus/Web of Science-indexed journal (World Journal of Gastroenterology), supporting B over C.

Metals frontmatter. The review explicitly names two of the HMTc 10-analyte list metals as MT substrates: cadmium and mercury (source p. 993, Characteristics of MTs — “MTs bind a number of trace metals including cadmium, mercury, platinum and silver”). Speciation is not addressed for either metal; the wiki-page metals frontmatter records Cd and tHg (total mercury) per the speciation-default rule in CLAUDE.md Part 14 (no methyl-vs-total distinction in the source → total mercury). Platinum and silver are not on the HMTc 10-analyte list and are not recorded. Vanadium, zinc, copper, and manganese also appear in the review but are not on the HMTc list and are not recorded. Pb, iAs, tAs, MeHg, Ni, Cr-VI, Al, and Sn do not appear substantively in this review.

Ingredients, products, matrices, jurisdictions frontmatter. All empty. The source measures nothing in any food, beverage, personal-care, or environmental sampling matrix; it reviews MT biology and tumour pathology. No ingredients: slug applies (the experimental systems are cell lines and rodent tumour models). No products: slug applies. No matrices: slug applies (the only “matrix” framing is liver, breast, skin, cervix, and pancreas tissue in human or rodent pathology, which is target-organ framing rather than HMI food-matrix sampling). No jurisdiction applies (the literature scope is international; authors are based in India but no national regulatory framework is applied).

Sample size. Null. This is a review with no sampling frame of its own.

Brand firewall (Part 12). No consumer-product brand names appear in the source. Scientific-method reagent and vendor names that do appear — Sigma (biotinylated secondary antibody supplier in the IHC protocol on p. 995), and the named cell line MCF-7 (p. 994) — are preserved under the Exception 2 (scientific-method vendor/material names) carve-out. No firewall action required.

HMTc firewall (Part 2). The review contains no HMTc-threshold language, no “consistent with the literature consensus” framing, and no consumer-audience risk advisories. The detoxification and chemo-resistance sections are presented as basic-science mechanism, not as cadmium- or mercury-exposure risk-assessment claims that could move HMTc thresholds. No firewall action required.

Scope fit. This paper is in scope per the 2026-06-02 commit 3f47f95 — scope: mitigation/remediation is in-scope, not a skip. The “Black Market Peptide Metal Survey” folder context is Karen’s peptide-metal literature harvest. This source is mechanistic background for cadmium and mercury biological handling and the MT-as-scavenger thesis; it does not address peptide-product contamination but does inform the broader metals-and-peptides programme.

Date arithmetic. Received 27 July 2006, accepted 10 January 2007, published 21 February 2007 — all consistent with the year frontmatter (2007) and the citation World J Gastroenterol 2007; 13(7): 993–996.

DOI provenance. The PDF does not print a DOI; the article carries only the article URL http://www.wjgnet.com/1007-9327/13/993.asp. The wiki-page frontmatter records doi: null with no_doi_assigned: true rather than fabricating a presumed 10.3748/wjg.v13.i7.993 DOI string. Should a DOI be confirmed independently via CrossRef in a later pass, update the frontmatter and the access URL together.

Audit subagent (2026-06-08) verdict: PROMOTE. Five checks (numerical fidelity, slug vocabulary, speciation/methods, brand firewall, HMTc firewall) returned ✅✅✅✅✅ with one minor location-pointer flag and no ❌ or ⚠️ at the verdict level. The flagged item: the Key-numbers table row “High-power fields scored per section | 10 (randomly chosen) | IHC scoring” attributed the Negative control paragraph to p. 996, but that paragraph appears at the top of journal page 995 (the Negative control section immediately precedes the References heading on the same page). Verified against the PDF and corrected from “p. 996” to “p. 995” in the Key numbers table. No firewall, slug-vocabulary, or numerical-fidelity changes were needed.

Page history

The five most recent substantive edits to this page. The full version history lives in git; when DOI minting comes online (see schema docs), each entry below will also link to a version-pinned DataCite DOI.